CG200745 is a recently developed HDAC inhibitor that inhibits class I and class II HDACs (Hyun et al. 2009) and is being tested in phase II clinical trials for its anti-cancer effects (CrystalGenomics 2019). Here, HDAC9 is linked to cancer.